Internet-Delivered Cognitive Behavioral Therapy for Children With Pain-Related Functional Gastrointestinal Disorders:

Maria Lalouni1,2, Brjánn Ljótsson3,4, Marianne Bonnert2,3,5

  • 1Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.

JMIR Mental Health
|August 12, 2017
PubMed

Insights

Internet-delivered cognitive behavior therapy (Internet-CBT) is a feasible and effective treatment for children with pain-related functional gastrointestinal disorders (P-FGIDs). This therapy significantly improved symptoms and quality of life, with results sustained at six months.

Area of Science:

  • Pediatric Gastroenterology
  • Child Psychology
  • Digital Health Interventions

Background:

  • Pain-related functional gastrointestinal disorders (P-FGIDs) are common in children, impacting quality of life and leading to anxiety and school absence.
  • Current treatment options for pediatric P-FGIDs are limited, necessitating the development of accessible and effective therapies.
  • Internet-delivered cognitive behavior therapy (Internet-CBT) has shown efficacy in adults and adolescents but requires evaluation in younger children.

Purpose of the Study:

  • To assess the acceptability and feasibility of Internet-CBT for children aged 8-12 with P-FGIDs.
  • To evaluate the potential clinical efficacy of this digital intervention in improving gastrointestinal symptoms and related outcomes.
  • To determine if parents find the intervention acceptable and if it aids in managing their child's pain behaviors.

Main Methods:

  • A feasibility study with a within-group design included 31 children (8-12 years) diagnosed with P-FGID (ROME III criteria).
  • Participants underwent 10 weekly modules of therapist-guided, exposure-based Internet-CBT, focusing on symptom provocation and avoidance behaviors.
  • Parental involvement included reducing attention to pain behaviors and reinforcing exposure work; outcomes were assessed pre- and post-treatment, and at 6-month follow-up.

Main Results:

  • High treatment completion rates (81%) and significant child-reported symptom improvement (87%) were observed.
  • A large effect size (Cohen d=1.14) for child-rated gastrointestinal symptoms was noted from pre- to post-treatment, maintained at 6-month follow-up (d=1.40).
  • Significant improvements were recorded in quality of life, pain intensity, anxiety, depression, and school absence, with sustained or further improved results at follow-up.

Conclusions:

  • Exposure-based Internet-CBT is perceived as acceptable and feasible by children with P-FGIDs and their parents.
  • The intervention demonstrated significant clinical efficacy, improving symptoms and associated functional impairments even in children with long-standing conditions.
  • Further confirmation in a randomized controlled trial (RCT) is warranted to solidify these promising findings for pediatric P-FGIDs.
Abstract

Related Concept Videos

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
981
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.2K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
967
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
927
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
960
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
783